HOUSE CONCURRENT RESOLUTION NO. 165
(By Delegates Guthrie, Paxton, Perdue, Barill, Pino, Eldridge, Lynch, Poore, Sobonya, Miller, Iaquinta, Ambler, Anderson, Arvon, Azinger, Barrett, Border, Campbell, Canterbury, Caputo, Craig, Diserio, Ellington, Espinosa, Evans, A., Faircloth, Ferns, Ferro, Fleischauer, Folk, Fragale, Hamilton, Hamrick, Hartman, Ireland, Jones, Kump, Lawrence, Longstreth, Manchin, Manypenny, Marcum, Marshall, Miley, Moore, Morgan, Moye, Pasdon, Perry, Pethtel, Phillips, L., Phillips, R., Poling, D., Poling, M., Raines, Reynolds, Romine, Rowan, Shott, Skaff, Skinner, Smith, R., Sponaugle, Stephens, Stowers, Swartzmiller, Tomblin, Walker, Wells, White, Williams and Young)
Requesting the Joint Committee on Government and Finance to study the issues of West Virginians' access to effective pain management medications and the need for the Bureau for Medical Services and the Public Employee Insurance Agency to require the adoption of abuse deterrent formulation technologies for pain medicines in order to assist in the state's continuing efforts to eliminate substance abuse.
Whereas, Over 100 million adults in the United States suffer from chronic pain, including millions with debilitating conditions like arthritis, fibromyalgia and lower back pain; and
Whereas, Chronic pain likely costs West Virginia millions of dollars each year in lost productivity, added health costs and increased expenditures for Medicaid; and
Whereas, The significant and justified concentration of attention on limiting substance abuse in our state has placed healthcare providers and patients in a difficult position as barriers to pain treatment have been considered; and
Whereas, New technologies are available that can protect the integrity of pain medications so they may not be altered in form for the ease of substance abusers to use illegally; and
Whereas, The federal Food and Drug Administration is currently studying the application of abuse deterrent formulation (ADF) technologies for use in opioid medications; and
Whereas, The introduction of ADF technologies into the pain medication arena is of great potential significance to West Virginia as a method to ensure the continued access of patients to these important medicines and to the general interests of the state as a strategy to limit substance abuse problems; therefore, be it
Resolved by the Legislature of West Virginia:
That the Joint Committee on Government and Finance is hereby requested to study the issues of West Virginians' access to effective pain management medications and the need for the Bureau for Medical Services and the Public Employee Insurance Agency to require the adoption of abuse deterrent formulation technologies for pain medicines in order to assist in the state's continuing efforts to eliminate substance abuse; and, be it
Further Resolved, That the Joint Committee on Government and Finance report to the regular session of the Legislature, 2014, on its findings, conclusions and recommendations, together with drafts of any legislation necessary to effectuate its recommendations; and, be it
Further Resolved, That the expenses necessary to conduct this study, to prepare a report and draft necessary legislation be paid from legislative appropriations to the Joint Committee on Government and Finance.